HBIO: היקף החוב לטווח ארוך Harvard Bioscience Inc.

Harvard Bioscience (HBIO) operations are constrained by US-China trade barriers and logistical disruptions in Asia. Stable revenue is driven by customer lock-in to specialized software and maintenance services. The share price retrospective demonstrates the 0.04 indicator. Current growth is supported by the upgrading of automated lines, enabling the company to more rapidly process the backlog of orders for precision equipment.

This metric reflects the total volume of liabilities with maturities exceeding twelve months, allowing for an assessment of long-term financial stability and leverage levels relative to industry peers. By analyzing the long-term debt statistics of Harvard Bioscience (HBIO), an investor can confirm the current priority of Harvard Bioscience (HBIO) to optimize margins and integrate assets during a temporary hiatus from new merger and acquisition deals.